

**Enhancing Access and Improving
Retention in Rare Disease Trials
with Home Trial Support**

A Musculoskeletal Case Study

Home Trial Support:

A Patient-Centric Solution for Better Outcomes in Musculoskeletal Research

For patients living with musculoskeletal conditions, participating in clinical trials can be challenging. Limited mobility due to pain, stiffness, or joint deterioration often makes traveling to clinical sites a significant obstacle. Musculoskeletal conditions often co-exist with other health issues, further complicating logistics and contributing to the burden of participation. **During this study, 48 patients were referred to Home Trial Support (HTS)**, addressing these challenges by offering a solution that reduces the need for travel and accommodates patients' individual needs.

HTS can provide a vital solution for overcoming recruitment challenges, ensuring broader and more equitable access to musculoskeletal clinical trials no matter where the patient lives. By enabling study visits to occur in patients' homes, HTS reduces physical strain, minimizes travel obstacles, and allows patients to receive care in a comfortable setting. HTS is a tried and tested retention solution. **This study achieved a 77% retention rate for the patients using in-home care, well above the 70% industry average.** Bringing trials to patients ensures timely completion of their trial participation.

Case Study Outcome

Indication: Musculoskeletal

Location: North America

HTS improves recruitment and retention in musculoskeletal trials by facilitating in-home visits, reducing travel burdens, and ensuring continuous data collection as patients' mobility declines.

Here's what our team was able to do...

- 48** Patients referred to Home Trial Support
- 1,908** Home Trial Support visits conducted during the study
- 77%** Patient retention rate to Home Trial Support
- 31%** Faster recruitment than the industry average




Key Outcomes & Impact Of HTS During The Study

HTS is particularly beneficial for musculoskeletal patients experiencing acute flares or relying on assistive devices for mobility. It enhances trial efficiency and data quality by increasing recruitment and making trials accessible to a wider patient population. It also retains participants who might otherwise drop out due to the burden of site visits.

For musculoskeletal studies, where patient comfort and consistency in care are critical, HTS services offer a patient-centric solution that fosters meaningful participation while advancing research toward improved treatments and outcomes.

In this study, recruitment was 31% faster than the industry average, underscoring the value of HTS in streamlining the process.



MRNs Experience With Rare Disease Studies

MRN has over **17+ years** of experience in **Rare Disease** studies, delivering various types of visits from blood draws, to visits with Investigational Product administration (IV Infusion, Subcutaneous injection and oral administration).

31 countries

supported with HTS services

49 sponsors

sponsors worked with

142 trials

supported with HTS services

1,295 sites

trained for Home Trial Support

50,190 HTS

visits performed

Delivering Quality And Maintaining Patient Safety

MRN is a global leader in Home Trial Support (HTS) services, bringing clinical trials to patients' homes to remove participation barriers and enhance trial efficiency. By expanding the geographical reach of clinical trials, HTS improves accessibility and inclusivity while ensuring trial visits fit patients' schedules.

For patients, HTS eliminates challenges like mobility limitations, travel distance, and scheduling conflicts. For sponsors and sites, it accelerates recruitment, improves retention, and enhances compliance, leading to better data and faster trial completion. **With 112,500+ home trial visits across 99+ countries and experience in 100+ indications**, MRN delivers trials across all phases and therapeutic areas.

Our healthcare professionals conduct in-home procedures, from patient training and assessments to complex drug administration and direct data capture. While visits happen at home, the Principal Investigator (PI) retains full oversight, ensuring trial integrity and patient safety.

MRN upholds the highest standards in patient and data safety. Our healthcare professionals complete rigorous, protocol-specific training with 100% accuracy, and we maintain **ISO27001 and ISO 9001:2015 accreditation** for strict regulatory compliance. With a proven track record in safe, efficient, and patient-focused HTS, MRN is making clinical trials more accessible and inclusive worldwide.

Delivering Community-Based Trials

focused on patients, focused on results

With our Home Trial Support services, we remove participation barriers by bringing trials to patients where they live, creating convenience and comfort that results in **increased recruitment and retention**.



Our project management and visit delivery team have a strong understanding of **global regulations for in-home care** and are able to collaborate directly with the Sponsor and country managers to expand services, ensuring patients receive necessary home visits as their needs grow.

“We act as a single provider with global delivery. This means we can scale quickly and efficiently to deliver where patients live.”

Stuart Redding, CEO, MRN



Our offices



UK

Medical Research Network Ltd
Milton Keynes



USA

Medical Research Network Inc.
Deerfield IL



Spain

Medical Research Network
Madrid



Germany

Medical Research Network Germany GmbH
Stuttgart-Vaihingen



Japan

Medical Research Network Japan KK
Tokyo



France

Medical Research Network,
Lyon



enquiries@themrn.co.uk



www.themrn.io

